Physician profile
Robert T Wall
NPI 1386627040
$7,952.01
in general payments reported to CMS, 2019-2025
55 companies · $4,607 in 2025
The $4,607 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,345 · 2025: $4,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,952.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $678.64 | 2024-2025 | Erleada, Balversa, Akeega |
| Novartis Pharmaceuticals Corporation | $615.34 | 2024-2025 | |
| Pfizer INC. | $501.92 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.00 | 2024-2025 | Enhertu, Tagrisso, Lynparza |
| Daiichi Sankyo INC. | $371.74 | 2024-2025 | Enhertu, Datroway |
| Eisai INC. | $285.83 | 2024-2025 | |
| Incyte Corporation | $269.04 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $243.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.08 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Stemline Therapeutics INC. | $226.30 | 2024-2025 | Orserdu, Elzonris |
| E.R. Squibb & Sons, L.L.C. | $209.65 | 2024-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $199.38 | 2024-2025 | Trodelvy |
| Sobi, INC | $184.00 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.95 | 2024-2025 | |
| Exelixis INC. | $172.11 | 2024-2025 | Cabometyx |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $170.88 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $154.98 | 2024-2025 | |
| Lilly USA, LLC | $153.04 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $150.91 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $150.83 | 2024-2025 | |
| Astellas Pharma US INC | $138.56 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Adc Therapeutics America, INC. | $127.16 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $120.50 | 2024-2025 | Xpovio |
| Genentech USA, INC. | $115.88 | 2024-2025 | Phesgo, Tecentriq Hybreza, Polivy |
| Pharmaessentia USA Corporation | $115.04 | 2024-2025 | Besremi |
| Puma Biotechnology, INC. | $110.95 | 2024-2025 | |
| Array Biopharma INC | $105.61 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Rigel Pharmaceuticals, INC. | $97.62 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Ipsen Biopharmaceuticals, INC | $94.88 | 2024-2025 | Onivyde, Somatuline Depot |
| Blueprint Medicines Corporation | $93.91 | 2024-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $93.37 | 2024-2025 | |
| Beigene USA, INC. | $80.43 | 2024 | Brukinsa |
| Emd Serono, INC. | $80.18 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $74.22 | 2024-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.09 | 2024-2025 | Gilotrif |
| Cumberland Pharmaceuticals, INC. | $72.72 | 2025 | Sancuso |
| Coherus Oncology, INC. | $67.26 | 2024-2025 | Loqtorzi |
| Agios Pharmaceuticals, INC. | $61.30 | 2025 | Pyrukynd |
| Progenics Pharmaceuticals, INC. | $58.48 | 2025 | |
| Aveo Pharmaceuticals, INC. | $57.82 | 2024-2025 | |
| Mirati Therapeutics, INC. | $57.77 | 2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $56.54 | 2025 | Provenge |
| Boston Scientific Corporation | $54.33 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Springworks Therapeutics, INC. | $49.13 | 2024-2025 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $48.30 | 2025 | Danziten |
| Iovance Biotherapeutics, INC. | $34.18 | 2025 | Amtagvi |
| Syndax Pharmaceuticals, INC. | $33.71 | 2025 | |
| Acrotech Biopharma INC. | $33.69 | 2025 | Beleodaq |
| Genmab U.S., INC. | $31.25 | 2024 | Epkinly |
| Pharmacosmos Therapeutics INC. | $29.06 | 2024 | Monoferric |
| Glaxosmithkline, LLC. | $27.90 | 2024 | Zejula, Jemperli |
| Legend Biotech USA INC. | $27.61 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $22.94 | 2024 | Qinlock |
| Geron Corporation | $22.15 | 2025 | Rytelo |
| Ge Healthcare | $21.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.